Stock 4891 TMS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TMS Co., Ltd.

Equities

4891

JP3544960002

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-05 am EDT 		5-day change 1st Jan Change
226 JPY -7.38% Intraday chart for TMS Co., Ltd. -10.67% +20.21%
Jul. 03 TMS to Make Upfront Payment to Hokkaido University for Licensing Agreement; Shares Fall Over 3% MT
Jul. 03 TMS Enters into Exclusive License Agreement with Hokkaido University to In-License Novel Therapeutic Candidate for Spinal Cord Injury CI

Valuation

Fiscal Period: February 2025 2026 2027
Capitalization 1 9,109 - -
Enterprise Value (EV) 1 9,109 9,109 9,109
P/E ratio -7.06 x -7.06 x -5.95 x
Yield - - -
Capitalization / Revenue - - 19.4 x
EV / Revenue - - 19.4 x
EV / EBITDA -7.2 x -7.06 x -5.99 x
EV / FCF -10.1 x -7.01 x -5.83 x
FCF Yield -9.88% -14.3% -17.2%
Price to Book - - -
Nbr of stocks (in thousands) 40,304 - -
Reference price 2 226.0 226.0 226.0
Announcement Date - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: February 2025 2026 2027
Net sales 1 - - 468.8
EBITDA 1 -1,265 -1,290 -1,521
EBIT 1 -1,275 -1,300 -1,531
Operating Margin - - -326.58%
Earnings before Tax (EBT) 1 -1,275 -1,300 -1,531
Net income 1 -1,275 -1,300 -1,531
Net margin - - -326.58%
EPS 2 -32.00 -32.00 -38.00
Free Cash Flow 1 -900 -1,300 -1,562
FCF margin - - -333.3%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period:
Estimates

Balance Sheet Analysis

Fiscal Period: February 2025 2026 2027
Net Debt - - -
Net Cash position - - -
Leverage (Debt/EBITDA) - - -
Free Cash Flow 1 -900 -1,300 -1,563
ROE (net income / shareholders' equity) - - -
ROA (Net income/ Total Assets) - - -
Assets 1 - - -
Book Value Per Share - - -
Cash Flow per Share - - -
Capex 1 10 10 10
Capex / Sales - - 2.13%
Announcement Date - - -
1JPY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
226 JPY
Average target price
760 JPY
Spread / Average Target
+236.28%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TMS CO., LTD. Stock TMS Co., Ltd.
+20.21% 56.69M
MODERNA, INC. Stock Moderna, Inc.
+18.97% 45.34B
LONZA GROUP AG Stock Lonza Group AG
+41.98% 40.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.06% 37.92B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+31.15% 31.75B
CELLTRION, INC. Stock Celltrion, Inc.
-7.79% 27.71B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.32% 26.52B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+43.05% 13.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.28% 12.44B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.41% 11.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4891 Stock
  4. Financials TMS Co., Ltd.